The go-ahead by the ministry this week comes as similar trials are ongoing in Azerbaijan, Argentina and United Arab Emirates...

The Hyderabad-based drug manufacturer is in a pact with Russian Direct Investment Fund to sell the first 125 million people doses in the country...

Need may reduce if more ingle-dose Covid jabs are approved...

The first batch of doses is expected to be produced at its facilities in September...

Vaccine makers intend to produce over 300 million doses of the vaccine in India per year, RDIF said in a statement...

Hyderabad-based firm to strengthen the commercial rollout of Russian jabs in the coming weeks...

The Indian govt expects 100 million locally produced and imported doses to be available in the country between August and December...

Panacea received the manufacturing licence from the Drugs Controller General (India) pursuant to its collaboration with the Russian Direct Investment Fund...

Subject Expert Committee notes that the phase-3 efficacy trial is ongoing in Russia and the efficacy data is yet to be generated...

Private centres now have to cap their prices at Rs 780 for Covishield, Rs 1,410 for Covaxin and Rs 1,145 for Sputnik V jabs...